Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Verona Pharma logo — Developing life enhancing treatments for chronic respiratory...

Verona Pharma

Developing life enhancing treatments for chronic respiratory diseases

Founded 2005 United Kingdom London, United Kingdom 195 employees Post-IPO Debt Total: $1.49B Biotechnology, Health and Wellness +1

General Information

Company Name Verona Pharma
Founded Year 2005
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 195
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Verona Pharma. To contact Verona Pharma, visit veronapharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Verona Pharma compare?

A PDF of Verona Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Verona Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company with a focus on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. The company's product candidate, ensifentrine, has shown potential to be the first therapy to combine bronchodilator and anti-inflammatory activities in one compound. The recent ENHANCE-1 and ENHANCE-2 trials demonstrated statistically significant and clinically meaningful improvements in lung function, meeting the primary endpoint. Additionally, ensifentrine significantly reduced the rate of COPD exacerbations. The management team at Verona Pharma is renowned for its established track record in the discovery, development, and commercialization of respiratory therapies. The company is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. While headquartered in London, UK, they also have offices in Raleigh and Savannah in the US. The most recent investment in Verona Pharma amounts to $650.00MPost-IPO Debt which took place on 09 May 2024. The investors in this round were Oaktree Capital and Ontario Municipal Employees Retirement System. With a strong focus on addressing critical medical needs, Verona Pharma presents a promising prospect for investors seeking opportunities in the biotechnology and pharmaceutical industries. For further information, visit Verona Pharma's website.

Business keywords: biopharmaceutical company, respiratory diseases, chronic conditions, ensifentrine, lung function improvement, COPD exacerbations, clinical-stage, Nasdaq listed, management team, innovative therapies, bronchodilator, anti-inflammatory activities, clinical trials, London headquarters, commercialization

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $650.00M 2
Oaktree Capital
Oaktree Capital, Ontario Municipal Employees Retirement System
09 May 2024
Post IPO Debt $400.00M 2
Hercules Capital
Hercules Capital, Oxford Finance LLC
02 Jan 2024
Post IPO Debt $150.00M 1
Oxford Finance LLC
17 Oct 2022
Post IPO Debt $30.00M 1
Silicon Valley Bank
23 Nov 2020
Post IPO Equity $200.00M 10
Novo Holdings RA Capital Management OrbiMed
Novo Holdings, RA Capital Management +8
17 Jul 2020
Post IPO Equity £44.70M 9
New Enterprise Associates Novo Holdings Abingworth
New Enterprise Associates, Novo Holdings +7
20 Jun 2016
Post IPO Equity $11.50M 1
Henderson Global Investors
Henderson Global Investors
06 Feb 2012

Verona Pharma Alternatives & Competitors

View All Alternatives
Verona Pharma vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
Compare Verona Pharma vs Antharis Therapeutics, Inc.
Verona Pharma vs
Immunic Therapeutics
Immunic Therapeutics United States

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and...

Post-IPO Equity
91 employees
Biotechnology, Health and Wellness
Compare Verona Pharma vs Immunic Therapeutics
Verona Pharma vs
Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. United States

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Verona Pharma

Developing life enhancing treatments for chronic respiratory diseases
Verona Pharma was founded in 2005.
Verona Pharma is headquartered in London, United Kingdom.
Verona Pharma operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceutical company, respiratory diseases, chronic conditions and ensifentrine.
Verona Pharma has approximately 195 employees.
Verona Pharma has completed 7 funding rounds, raising a total of $1.49B. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Verona Pharma include Antharis Therapeutics, Inc., Immunic Therapeutics, Lisata Therapeutics, Inc., SetPoint Medical, PaxMedica, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Verona Pharma and Antharis Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Verona Pharma, https://bouncewatch.com/company/verona-pharma, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout